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Abstract
Classic cancer research for several decades has focused on understanding the biology of tumor cells in vitro. How-
ever, extending these findings to in vivo settings has been impeded owing to limited insights on the impact of
microenvironment on tumor cells. We hypothesized that tumor cell biology and treatment response would be more
informative when done in the presence of stromal components, like endothelial cells, which exist in the tumor micro-
environment. To that end, we have developed a system to grow three-dimensional cultures of GFP-4T1 mouse mam-
mary tumor and 2H11 murine endothelial cells in hanging drops of medium in vitro. The presence of 2H11 endothelial
cells in these three-dimensional cocultures was found to sensitize 4T1-GFP tumor cells to chemotherapy (Taxol) and,
at the same time, protect cells from ionizing radiation. These spheroidal cultures can also be implanted into the dorsal
skinfold window chamber of mice for fluorescence imaging of vascularization and disease progression/treatment re-
sponse. We observed rapid neovascularization of the tumor-endothelial spheroids in comparison to tumor spheroids
grown in nude mice. Molecular analysis revealed pronounced up-regulation of several proangiogenic factors in the
tumor tissue derived from the tumor-endothelial spheroids compared with tumor-only spheroids. Furthermore,
the rate of tumor growth from tumor-endothelial spheroids in mice was faster than the tumor cell–only spheroids,
resulting in greater metastasis to the lung. This three-dimensional coculture model presents an improved way
to investigate more pertinent aspects of the therapeutic potential for radiation and/or chemotherapy alone and in
combination with antiangiogenic agents.
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Introduction
Development of malignancy and response of tumors to therapy de-
pends on their ability to adapt to different environments, compete
with normal cells for space and nutrients, and ignore molecular sig-
nals that inhibit cell proliferation and promote cell death [1]. The
process of initiation and development of the tumor involves (i) the
assembly of the proliferating tumor cells into a three-dimensional
structure termed tumorigenesis and (ii) a complex interaction between
tumor cells and their microenvironment termed tumor angiogenesis
where host endothelial cells (and various other types of cells) are
recruited to contribute to the formation of tumor vasculature to
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provide an adequate supply of oxygen and nutrients for the growing
tumor mass.
Existing preclinical tumor cell in vitro models have not explicitly
incorporated angiogenesis and thus have ignored the interaction be-
tween tumor and endothelial cells in vitro. In addition, studies on
in vitro two-dimensional monolayer cell cultures and their translation/
extension to clinical settings have their limitations because they
are not capable of mimicking the nutrient and oxygen gradient
and an environment reminiscent of the in vivo setting [2–4]. Fur-
thermore, obtaining fresh tumor samples in clinical settings can be
especially challenging and provides limited possibilities for manipu-
lation. Clinical samples have also been shown to exhibit considerable
heterogeneity for a wide variety of reasons [5,6]. Although the ratio-
nale behind the use of antiangiogenic and antivascular therapy is
solid, a major factor in the somewhat disappointing and even sur-
prising results of the first tumor vasculature–targeted agent human
clinical trials may be owing to limitations in the in vitro and in vivo
animal models used to date [7,8]. Therefore, a preclinical in vitro
model that can facilitate the intra/intercellular crosstalk mimicking
the in vivo tumor and endothelial cell architecture and, more im-
portantly, lend itself for controlled experimental manipulation and
replication would be extremely valuable for interrogating these in-
teractions between tumor parenchyma and stroma to better under-
stand the mechanisms of radiation and cancer therapeutics and
promote the establishment of improved pharmacokinetics, efficacy,
and safety profiles.
Techniques that allow a coculture of tumor and stromal cells to
promote a realistic self assembly into three-dimensional spheroids
have been rarely studied to any great detail thus far in the litera-
ture. An attempt in this direction was made by Timmins et al. [9]
to generate three-dimensional tumor-endothelial spheroids in
hanging drops of medium. However, this approach has not evolved
beyond its nascent stage, possibly because of the lack of discovery
and validation at a molecular level of important signaling mecha-
nisms involved in tumor angiogenesis and the fact that the spher-
oids were not transplanted into animal models for studying cancer
progression and ultimately metastasis. We have recently discovered
that certain pairs of endothelial and tumor cell lines grow exceed-
ingly well together in a hanging drop, compared with either cell
type alone. In the current study, we have used the GFP-4T1 mouse
mammary tumor cells and 2H11 murine endothelial cells as a
three-dimensional coculture model for studying the effects of
treatment on tumor angiogenesis and tumor cell survival and have
monitored tumor growth and metastatic activity by implanting
these tumor-endothelial spheroids in the dorsal skinfold window
chamber or rear limb of immunocompromised mice. Using this
system to coculture tumor and endothelial cells in three dimen-
sions, we have monitored response to chemotherapy or radiother-
apy in vitro and in the development of vessels and tumor growth
and metastasis in vivo. This in vitro/in vivo tumor-endothelial co-
culture is, to our knowledge, the first preclinical model that is able
to provide an understanding of cancer in a continuum—from ini-
tiation to development and progression. Our primary goal was to
use this system to understand more accurately the mechanisms by
which primary or metastatic tumor tissue grows and responds to novel
angiogenesis-targeted treatments and radiation therapy. We surmise
that this in vitro/in vivo preclinical mouse model will not only enable
the identification of authentic and novel biomarkers but also provide
enhanced predictive utility for drug development and discovery.
Materials and Methods
Cell Lines and Culture
GFP-4T1 [10] is a green fluorescent protein (GFP)–expressing
mouse metastatic mammary epithelial cell line that is resistant to
Taxol [11]. The 2H11 cell line was validated as a tumor-like endo-
thelial cell line by Walter-Yohrling et al. [12]. Most endothelial cell
lines being used to study angiogenesis have been immortalized using
SV40 and express the SV40 T antigen, with the assumption that
SV40 is nonpermissive in murine cells. Although transformed, these
cell lines tend to retain most of the normal cellular physiology and
functional characteristics of endothelial cells. 2H11 is one such endo-
thelial cell line originally generated by O’Connell and Rudmann [13],
O’Connell and Edidin [14], and O’Connell et al. [15] from endo-
thelial cells isolated from lymph nodes of adult C3H/HeJ mice trans-
formed using SV40 displaying characteristics of Kaposi sarcoma. This
cell line is most well characterized by the presence of several attributes
typical of normal endothelial cells and those of endothelial cells di-
rectly isolated from tumors. Walter-Yohrling et al. [12] thus termed
this cell type as tumor-endothelial cells. The standard endothelial cell
markers found in this cell type, some of which we have also verified in
this article, include sialomucin/CD34, GPIIIB/CD36, endogolin/
CD105, P1H12/CD146, VCAM1/106, Tie-1, and Tie-2. The tumor-
endothelial markers that are expressed in relatively high levels include
mTEM1, mTEM5, mTEM7, and mTEM8. This murine endothelial
cell line also responds to antiangiogenic agents by inhibition of pro-
liferation and tube formation. It has been identified as a murine
endothelial cell line to model tumor endothelium for studying the anti-
angiogenic activity of therapeutic compounds in vitro and is therefore
our choice for representing the endothelial component in our model.
The cell lines were maintained as monolayer culture at 37°C and 5%
CO2 in Dulbecco modified Eagle medium (Mediatech,Manassas, VA),
supplemented with 10% fetal bovine serum (Atlas, Fort Collins, CO),
100 U/ml penicillin, and 100 μg/ml streptomycin (HyClone, South
Logan, UT).
Chemicals and Reagents
Paclitaxel (Taxol), dimethyl sulfoxide (DMSO), and MitoTracker
Red CMXRos were purchased from Sigma-Aldrich, Inc (St Louis,
MO), Research Organics (Cleveland, OH), and Invitrogen (Carlsbad,
CA) respectively. Antibodies to murine NOV/CCN3, murine inter-
leukin 1α, and rat matrix metalloproteinase 8 (MMP-8) for reverse-
phase immunoblot analysis were obtained from R&D Systems
(Minneapolis, MN). The glyceraldehyde-3-phosphate dehydrogenase
antibody was from Cell Signaling Technology (Danvers, MA). The
MMP-9 antibody was obtained from Abcam (Cambridge, MA). The
antibodies galectin-1 (Santa Cruz Biotechnology, Santa Cruz, CA),
CD34 (BD Pharmingen, Sparks, MD), and human von Willebrand
factor (vWF; Dako Denmark A/S, Glostrup, Denmark) were used
for immunoblot analysis and immunostaining to identify the tumor-
endothelial cells in spheroids.
Spheroid Culture in “Hanging Drop”
GFP-4T1 tumor cells and 2H11 endothelial cells were used to
generate multicellular spheroids by growing them as “hanging drops”
of medium (in Dulbecco modified Eagle medium with 10% fetal bo-
vine serum and antibiotic/antimycotic mix) [16]. Briefly, single-cell
suspension of GFP-4T1 cells (1000 cells/20 μl) was dispensed on the
inside of the lid of each well of a 48-well cell culture plate (Greiner
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Cellstar, BioExpress, Kaysville, UT). Gravity-enforced self-aggregation
of cells was facilitated by inverting the lid and setting it on the plate
and incubating under standard conditions. At day 3, the lids were set
upright, and 2000 cells in a volume of 5 μl, 2H11 endothelial, or ad-
ditional GFP-4T1 tumor cells were introduced to the existing culture.
These cultures were reinverted and left as hanging drops and incubated
further for 10 to 14 days. The day tumor or endothelial cells were re-
introduced to the tumor cell aggregates in the hanging drop of medium
was taken as day 1 in all experiments. Introduction of 1/10th the num-
ber of tumor or endothelial cells to the existing hanging drop culture of
4T1 tumor cells did not change the pattern of growth and morphology
of the spheroids (Figure W1). Because the proliferation of cells in
spheroids is not as fast as that observed in monolayer cell cultures and
to generate adequate numbers of each cell type from the spheroids to
assess the treatment response when tumor and endothelial cells were
in contact, we opted to do our experiments using spheroids prepared
by the introduction of 2000 cells to the existing culture (1:1 ratio).
The three-dimensional spheroids composed of GFP-4T1 cells alone are
referred to as tumor cell–only spheroids and those formed by the cocul-
ture of 4T1 and 2H11 cells types are referred to as tumor-endothelial cell
spheroids in the rest of this report. Both tumor cell–only and tumor-
endothelial cell spheroids remain intact and viable at day 10, and there-
fore, all in vitro and in vivo experiments have been done using spheroids
at day 10 of culture in hanging drops.
Immunohistochemistry
Spheroids were harvested and frozen in OCT (Tissue-Tek, Sakura
Finetek USA, Inc, Torrance, CA). A total of 6 to 10 spheroids were
embedded in each OCT block. Five- micrometer cryostat sections
were immunohistochemically analyzed using standard protocols. The
primary antibodies used recognized CD34 at a dilution of 1:50 or
vWF at a dilution of 1:200. Fluorescent visualization was performed
with 1:200 Northern Lights antirat IG-NL557 (R&D Systems) and
1:200 Cy 3 (Jackson ImmunoResearch Laboratories, Inc, West Grove,
PA) antibody, respectively, and counterstained with Vectashield
Mounting Medium with 4′,6-diamidino-2-phenylindole (Vector,
Burlingame, CA). Slides were observed at 10×, 20×, or 40× using
Olympus IX71 microscope and images taken by an Olympus DP72
camera (Olympus, Tokyo, Japan).
Hematoxylin and Eosin Staining and Imaging
Hematoxylin and eosin (H&E) staining was performed by staining
the cryostat sections with Harris hematoxylin (aluminum potassium
sulfate, hematoxylin, absolute alcohol, mercuric oxide, and glacial
acetic acid) followed by 1% acid alcohol and, subsequently, 1% eosin.
Images of spheroids were taken at 10× using Olympus IX71 micro-
scope and Olympus DP72 camera. Tissue imaging was performed
using an Aperio ScanScope (Aperio, Vista, CA) at 20× magnifications
and analyzed using ImageScope software (Aperio).
Stabilization of Spheroids and Confocal Microscopy
Tumor-endothelial cell spheroids consisting of the GFP-4T1
murine mammary epithelial cancer cells stably expressing GFP and
the 2H11 murine tumor-endothelial cells and the tumor cell–only
(GFP-4T1) spheroids were incubated with 1 μM of MitoSOX Red
(Invitrogen) at 37°C for 10 minutes followed by washing twice
with phosphate-buffered saline (PBS). The spheroids were then
fixed for 3 hours at 4°C in 1% parafomaldehyde (EUROMEDEX,
Mundolsheim, France) and washed twice with PBS. SeaPlaque low-
melt agarose (0.8%; FMC BioProducts, Rockland, ME) was pre-
pared for use as described by the manufacturer, cooled on ice, and
made isotonic by the addition of 40× PBS. SeaPlaque low-melt
agarose was added to the spheroids, and then they were loaded onto
cooled slides. Double-sided tape was used between the slide and
coverslipped to maintain the shape of the tumor spheroids. Imaging
was performed using a confocal laser scanning system (LSM 510;
Carl Zeiss, Peabody, MA).
Cell Death Assay
At day 10, the spheroids were transferred to a low-binding 96-well
plate (Nalgene, Nunc, Japan) and subjected to treatment with drug
for 48 hours. After drug treatment, spheroids were dissociated using
trypsin. The three-dimensional spheroids developed an extracellular
matrix, making it extremely difficult to dissociate the cells; we there-
fore passed the cells after dissociation through a 40-μm filter to avoid
the presence of cell clusters. The suspension is diluted to a concentra-
tion of 5 × 104/ml for measurement of apoptosis using a cell death
detection ELISA kit (Roche, Indianapolis, IN). This is a quantitative
photometric immunoassay for the determination of cytoplasmic
histone-associated oligosomes generated during apoptosis. After dilu-
tion, cells were centrifuged at 200g for 5 minutes, and the cell pellet
was resuspended in 0.5 ml of incubation buffer and incubated at
room temperature for 30 minutes. After centrifugation at 16,000g
for 10 minutes, 0.4 ml of supernatant was removed and diluted 1:10
in incubation buffer for analysis. The ELISA plate was prepared ac-
cording to the manufacturer’s instructions, and 0.1 ml of sample was
added to the appropriate wells and incubated at room temperature for
90 minutes. After conjugation and incubation with substrate solution,
the plate was shaken on an orbital shaker at 250 rpm for 15 minutes,
and the absorbance at 405 nm was determined using an ELx800
microplate reader (BioTek, Winooski, VT).
Fluorescence Assay
The tumor cell–only and the tumor-endothelial cell spheroids were
transferred to low binding 96-well plates at day 10, and emission of
fluorescence was read at 510 nm using a Synergy 2 Multi-Mode
Microplate Reader (BioTek). The spheroids were subjected to treat-
ment with Taxol for 48 hours after which the fluorescence intensity
was read again. The relative decrease in fluorescence was calculated to
assess the response of 4T1 tumor cells to Taxol in the presence of
2H11 endothelial cells.
Survival Assay
The tumor cell–only and tumor-endothelial cell spheroids were
transferred to low-binding 96-well plates and irradiated at 2 Gy.
Spheroids of each type were pooled and trypsinized, cell clusters were
removed by passing through a 40-μm filter, and 200 to 8000 cells of
each treatment were plated in triplicate onto a six-well culture dish.
Phase-contrast and fluorescence images were taken 2 weeks after plat-
ing. A final cell count after 2 weeks for each set was done to estimate
the overall survival.
Animals
Female, athymic, nude mice (8-9 weeks old, 20-22 g) were purchased
from Charles River Laboratories (Wilmington, MA) and housed in the
animal care facility of the University of Arkansas for Medical Sciences.
All experiments were carried out in accordance with protocols approved
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by the Institutional Animal Care and Use Committee at the University
of Arkansas for Medical Sciences. The mice were given clean water
ad libitum and 2016 Teklad Global 16% Protein Rodent Diet (Harlan
Feeds, Woodland, CA).
Animal Model and Surgical Techniques
All surgical procedures were performed in a sterile field. Dorsal
skin window chambers and surgical instruments were autoclaved be-
fore use. Saline used to keep tissue moist during surgical preparation
was mixed with gentamicin (50 μl/ml).
Dorsal skinfold window chamber model. The dorsal skin window
chamber in the mouse was prepared as described [17,18]. Briefly,
female mice (20-22 g body weight) were anesthetized (inhalant
isoflurane at 3% maintenance) and placed on a heating pad. Two
symmetrical titanium frames were implanted into a dorsal skinfold,
to sandwich the extended double layer of skin. An approximately
15 × 15-mm2 layer was excised. Two three-dimensional spheroids
of each type at day 10 after coculture in hanging drops of medium
were placed on the underlying cutaneous maximus muscle and sub-
cutaneous tissues of each mouse, which were subsequently covered
with a glass coverslip incorporated in one of the frames. After a re-
covery period of 1 to 2 days, the windows were imaged for neo-
vascularization using an Olympus IX71 microscope and an Olympus
DP72 camera.
Blood Vessel Extraction Using MATLAB
Using a computer program created in house, two-dimensionally
projected vascular networks were produced from the region of interest
selected from images recorded with the 4× objective. The algorithms
used for identification of the vascular networks were implemented by
use of the MATLAB software (MathWorks, Natick, MA). The extrac-
tion technique involved a series of filtering, threshold, and other mor-
phologic image analysis procedures to get vascular tree structure.
Finally, binary images of blood vessel structure were assigned the
intensity of the input image [19].
Rear limb model. A small incision was made in the right hind
limb above the ankle and two three-dimensional spheroids at day 10
after coculture in hanging drops of medium were implanted in the
exposed subcutaneous tissue of each mouse. The incision was then
sutured with tissue adhesive (3M VetBond, St Paul, MN). Tumor
growth was recorded by caliper measurement. The mean of two per-
pendicular diameters was obtained. Tumor diameters were measured
Figure 1. Hanging drop cultures of three-dimensional spheroids. (A) Bright field and fluorescence images of GFP-4T1 mouse mammary
metastatic carcinoma cells alone (tumor cell only; upper panel) and grown in association with 2H11 murine endothelial cells (tumor-
endothelial cells; lower panel) as three-dimensional spheroids in hanging drop cultures for 7 days. Bar, 100 μm. (B) Confocal microscopy
of tumor cell–only (GFP-4T1) and tumor-endothelial cell (GFP-4T1–2H11) spheroids at day 7 after coculture after labeling with live cell-
permeant MitoTracker Red that stains the mitochondria. The regions where the red and green do not colocalize in the tumor-endothelial
spheroid overlay indicate the presence of 2H11 endothelial cells. Images are an overlay of green fluorescence (green) and MitoTracker
Red (red). (C) H&E staining of cryostat sections of spheroids at 10× and 40×, 10 days after coculture. (D) Growth of GFP-4T1 and GFP-
4T1–2H11 spheroids in hanging drops followed by transfer to low-binding 96-well plates at 6, 9, and 12 days after coculture.
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each day. The animals were killed at the end of 33 days. Lung and
spleen were excised to observe green fluorescence (GFP-4T1) indicative
of possible metastasis.
Intravital Fluorescence Microscopy
The dorsal skinfold window chamber model allows for intravital
imaging of the tumor growth and neovascularization. Because the
4T1 tumor cells were GFP positive, the normal and tumor tissue could
be easily differentiated. Fluorescence microscopy was performed using
an Olympus IX71 microscope, and digital images were taken every
4 days after the window chambers were implanted using an Olympus
DP72 camera.
Mouse Angiogenesis Antibody Array
The mice were killed on day 16 after implantation. Tumors originat-
ing from tumor cell–only and tumor-endothelial cell three-dimensional
spheroids were excised and homogenized in 400 μl of lysis buffer
(25 mM HEPES, pH 7.5, 0.5% sodium deoxycholate, 5 mM EDTA,
5mMdithiothreitol, 20mMglycerophosphate, 1mMNa3VO4, 50mM
NaF, 1%Triton X-100, 20 μg/ml aprotinin, 50 μg/ml leupeptin, 10 μM
pepstatin, 1 μM okadaic acid, and 1 mM phenylmethylsulfonyl fluo-
ride). The lysates were incubated at 4°C and passed through a 21-gauge
syringe 10 times, and the insoluble material was removed by centrifu-
gation (15 minutes at 12,000g). The protein concentration was deter-
mined using the Bio-Rad protein assay. Two hundred micrograms of
lysate was hybridized to a mouse angiogenesis antibody array (R&D
Systems) as instructed.
Pathway Analysis
The Ingenuity Pathway Analysis Tool was used to generate sig-
nificant gene networks and examine the functional associations be-
tween differentially expressed proteins in the angiogenesis arrays
obtained from incubation with lysates of tumors originating from
GFP-4T1 tumor and GFP-4T1–2H11 tumor-endothelial spheroids
(www.ingenuity.com).
Immunoblot Analysis
Lysates from the three-dimensional spheroid of each type were
prepared in the lysis buffer as described. About 10 to 20 spheroids
were incubated in the lysis buffer described above at 4°C for 1 hour on
NUTATOR (Benchmark Scientific, Inc, Edison, NJ). Cell debris was
removed by centrifugation (15 minutes at 12,000g). Immunoblot
analysis was performed using 50 μg of protein/lane and standard poly-
vinylidene fluoride membrane transfer followed by probing with the
respective antibody and chemiluminescent detection of the bands.
Figure 2. Molecular identification of the endothelial component in the tumor-endothelial cell spheroids. (A) Five-micrometer cryo-
sections of GFP-4T1–2H11 spheroids were analyzed by immunofluorescence at 20× with primary antibodies for CD34 (a marker for
tumor-endothelial cells [upper panel]) and vWF that recognizes endothelial cells (lower panel) with Texas Red–labeled secondary anti-
body for detection. Left to right: (a) DAPI, (b) immunofluorescent signal alone, and (c) overlay. (B) Lysates from GFP-4T1 and GFP-4T1–
2H11 spheroids 10 days after coculture were probed for expression Galectin-1 and CD34 by Western immunoblot analysis for the pres-
ence of tumor-endothelial–specific cells.
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Statistical Analysis
Data are expressed as mean ± 1 SD of at least three different
experiments unless otherwise mentioned. Statistical significance
of difference in means was performed using the parametric two-
sample t test with unequal variance (MathWorks). The corre-
sponding P values are shown for each of the comparisons under
the respective sections.
Results
Tumor Cell–Only Versus Tumor-Endothelial Cell Spheroids
By day 6 after beginning of the cocultures, the three-dimensional
tumor cell–only spheroids (4T1) grew up to a diameter of approxi-
mately 200 μm, whereas the tumor-endothelial cell spheroids reached
a size of approximately 400 μm in hanging drops of medium
(Figure 1A). The tumor-endothelial cell spheroids grew to 800 μm
when transferred to low-binding 96-well plates by day 12, remaining
very round and viable even after 2 weeks (Figure 1D). Confocal micros-
copy using MitoTracker Red, a dye that stains the mitochondria red
in living cells, was performed to establish these three-dimensional forms
as spheroids. Whereas the 4T1 tumor cells were detected by the ex-
pression of the GFP, the mitochondrial staining of 2H11 endothelial
cells made them fluoresce red in the overlay of red and green fluorescent
images (Figure 1, B and D). The confocal images clearly indicated a
physical interaction between tumor and endothelial cells. The tumor
cell–only spheroids, which were almost half the size (Figure 1B), how-
ever, showed a tendency of disintegrating into clumps by day 8 onward
and, when transferred to low-binding 96-well plates, started to adhere to
the bottom and acquire a monolayer cell culture phenotype by day 10.
H&E-stained sections of the spheroids in hanging drops at day 10 also
confirmed a compact spheroid with small luminal structures formed in
tumor-endothelial cell spheroids. On the contrary, H&E sections of
spheroids prepared with tumor cells only revealed a loosely packed, dis-
integrating spheroidal form with large luminal structures (Figure 1C).
Therefore, the 9- to 12-day window was used for treatment and for
assessing the response of the spheroids to drugs and radiation in vitro
studies. The spheroids were kept in the 96-well plates for not more than
48 hours for any of the in vitro studies.
Endothelial Cell Identification in
Tumor-Endothelial Spheroids
We assessed the distribution of vWF, an endothelial cell marker
and CD34, a protein that is expressed in tumor-endothelial cells by
immunostaining of tumor-endothelial spheroid sections. Interest-
ingly, the distribution of these proteins in the tumor-endothelial
spheroids revealed that the endothelial cells, although introduced to
the hanging drops of GFP-4T1 tumor cells at day 3, were able to pen-
etrate into the core, initiating short tube-like formations (Figure 2A).
Immunoblot analysis for galectin-1 and CD34 in lysates prepared
from tumor cell–only and tumor-endothelial spheroids showed an
Figure 3. Presence of 2H11 murine endothelial cells in the three-dimensional spheroid cocultures with GFP-4T1 tumor cells sensitizes
the Taxol-resistant GFP-4T1 cells to Taxol. (A) Relative cell death in control- and 2 μM Taxol–treated tumor cell–only or tumor-endothelial
cell spheroids assessed at 48 hours using a cell death ELISA kit (Roche). (B) Relative decrease in fluorescence after Taxol treatment in
the three-dimensional spheroids. (C) Relative cell survival 2 weeks after Taxol treatment.
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elevated expression of these tumor-endothelial cell–specific proteins in
the tumor-endothelial spheroids (Figure 2B). Galectin-1 overexpression
in recent reports has been shown to be associated with the tumor micro-
environment, particularly in response to the tumor and endothelial cell
interaction [20,21].
Response of Tumor and Tumor-Endothelial Spheroids to Taxol
The presence of murine 2H11 endothelial cells in three-dimensional
spheroids generated from GFP-4T1 (a normally Taxol-resistant cell
line) [11] made them more sensitive to Taxol treatment. We observed
approximately 50% more cell death and 33% relative decrease in green
fluorescence signal when normalized to treatment with DMSO in
tumor-endothelial spheroids when compared to tumor cell–only
spheroids (Figure 3, A and B) by 48 hours of exposure to 2 μM Taxol.
Because these experiments were performed in extremely low-volume
and high-drug concentration that was dissolved in DMSO, we have
normalized all the results to DMSO-alone treatment. The cells from
spheroids 48 hours after Taxol treatment were replated to assess sur-
vival after 2 weeks. The relative cell survival in the cells derived from
the tumor-endothelial spheroids after treatment correlated with the
previous results and was approximately 50% less than the tumor cell–
only spheroids (Figure 3C).
Response of Tumor and Tumor-Endothelial Spheroids
to Radiation
Exposure of tumor-endothelial spheroids after transfer to low-
binding 96-well plates to 2 Gy of ionizing radiation caused a decreased
amount of radiation-induced cell death in the tumor cells. With the
intention to perform clonogenic assays, a suspension was prepared from
tumor or tumor-endothelial spheroids after irradiation, and 8000 cells
were plated/well. No distinct colonies were obtained at 2 weeks
after culture. However, phase-contrast and fluorescence images
(Figure 4A) and total cell count (Figure 4B) showed a significant
increase in the number of GFP-4T1 tumor cells in cultures originating
from tumor-endothelial spheroids after irradiation in comparison to
those initiated from tumor cell–only spheroids.
Figure 4. Presence of 2H11 endothelial cells in the three-dimensional spheroid cocultures with GFP-4T1 tumor cells protects the GFP-
4T1 cells from radiation. (A) The tumor cell–only and tumor-endothelial three-dimensional spheroids were irradiated at 2 Gy; multiple
spheroids of each type were pooled together, trypsinized, and plated as indicated onto a six-well culture dish. Phase-contrast and fluo-
rescence images were taken 2 weeks after plating. (B) The graph depicts the final cell count after 2 weeks.
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Neoangiogenesis and Molecular Analysis of Angiogenic Factors
in Tumors Originating from Tumor Cell–Only Versus
Tumor-Endothelial Cell Spheroids in Dorsal Skinfold
Window Chamber Implants of Athymic Nude Mice
Tumors initiating from transplanted tumor-endothelial cell spher-
oids implanted at day 10 after coculture showed rapid neovasculariza-
tion within 14 days after implantation. Despite the fact that we had
added double the number of tumor cells in the tumor cell–only spher-
oids, they showed little evidence of vascularization in this time frame
(Figure 5A) and required approximately 26 days to get to the same level
of neovascularization (data not shown). Blood vessel extraction using
the vascular segmentation MATLAB code showed a distinct network
of vessel in the tumor-endothelial cell spheroid implants. In the tumor
cell–only spheroid implants, the vessels formed were in short discontin-
uous stretches (Figure 5B). Lysates from tumors excised from window
chambers at 14 days after implantation were probed for the presence
of 53 angiogenic factors using the customized Mouse Angiogenesis
Antibody Array from R&D Systems. Many proangiogenic factors
were upregulated in the tumors originating from tumor-endothelial
cell spheroids in comparison to the tumors obtained from tumor
cell–only spheroids (Figure 6A). Ingenuity pathway analysis revealed
that several of them were functionally associated (Figure 6B). Four of
Figure 5. Profuse neovascularization in window chamber implanted with tumor-endothelial spheroid. (A) Images (4×) of window cham-
bers implanted with tumor-endothelial spheroids showing profuse neovascularization by 14 days (lower panel) in comparison to 4T1
tumor spheroids alone (upper panel). Bar, 200 μm. (B) Vascular tree structure of blood vessels in the window chamber implants at day 14
after implantation. Left panel, Image in grayscale of the vascular structure. Right panel, Vascular tree structure was extracted using MATLAB-
based vessel extraction technique, and the binary images extracted were assigned with an initial image intensity profile.
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the significantly upregulated and functionally associated angiogenic pro-
teins such as interleukin 1α, nephroblastoma overexpressed (NOV/
CCN3), and members of the matrix metalloproteinase family (MMP-
8 and -9) were then selected to be validated by Western immunoblot
analysis. Interestingly, the expression of these four proteins while upregu-
lated in the tumor lysates from tumor-endothelial cell spheroids com-
pared with lysates of tumors from tumor cell–only spheroids was
completely absent in whole-cell lysates of GFP-4T1 tumor or 2H11 en-
dothelial cells growing in two-dimensional cultures (Figure 6, C and D).
Tumor Progression and Metastasis from Tumor Cell–Only
Versus Tumor-Endothelial Cell Spheroids Implanted in
Rear Limb of Athymic Nude Mice
Tumor cell implants in the rear limb have been used in many
studies as an in vivo murine model to reliably measure tumor
growth/volume by the caliper method [22–25] and are routinely per-
formed in our laboratory [26,27]. When inoculated subcutaneously
into the rear limb of mice, tumors originating from tumor-endothelial
cell spheroids were palpable noticeably earlier than in tumors origi-
nating from the tumor cell–only spheroids. These spheroids were in-
oculated in duplicate at days 10 and 21 of coculture in hanging drops.
Relative tumor growth in both sets of animals was greater in the tumors
originating from 4T1-2H11 spheroids (Figure 7A). The mice inoculated
with spheroids at days 10 and 21 in hanging drops were killed at days 33
and 45, respectively, after implantation. The metastasis was clearly more
pronounced in mice when analyzed for GFP signal in lungs from tumor-
endothelial spheroid implanted mice (Figure 7, B and C ). Further,
metastatic lesions were more numerous and larger in H&E-stained lung
sections from mice bearing primary tumors originating from the tumor-
endothelial cell spheroids (Figure 7D).
Discussion
Preclinical cell and animal models for cancer are typically used (i) to
serve as an aid in the investigation of the basic biologic principles of
Figure 6. Pronounced up-regulation of angiogenic factors in tumor tissue derived from tumor-endothelial spheroid dorsal skinfold im-
plant in nude mice. (A) Mouse angiogenesis antibody array: Quantification of pixel intensity as a measure of protein expression from
lysates of tumor tissue derived from tumor cell–only and tumor-endothelial cell spheroids grown in window chamber of nude mice. (B)
Ingenuity pathway analysis showing the interaction of some of the angiogenic proteins overexpressed in the tumor tissue derived from
tumor-endothelial cell spheroids in comparison to the tumor cell–only spheroids. (C) Mouse angiogenesis antibody array blots probed
with tumor lysates from GFP-4T1 and GFP-4T1–2H11 showing the expression of proteins that were selected for reverse-phase immu-
noblot analysis. (D) Validation by Western blot of four angiogenic factors distinctly upregulated in the lysates from tumor-endothelial
spheroid–derived tissue and not in the 4T1 and 2H11 cells grown in monolayer cell cultures.
Translational Oncology Vol. 4, No. 6, 2011 Tumor-Endothelial Cell Three-dimensional Spheroids Upreti et al. 373
cancer, (ii) as an assay for the preclinical development of anticancer
drugs or (iii) as a tool for discovering new clinical agents and assays.
One of the most important concepts in preclinical modeling is
“predictive utility” [28], and this is especially a critical need for the
field of antiangiogenesis research where surrogate markers for activity
and/or effect have been difficult to uncover. The culture of tumor
cells within natural and synthetic extracellular matrix mimics and
three-dimensional microenvironment conditions has been shown to
clearly alter tumor cell signaling and has led to the development of
more pathologically relevant cancer models [29–32]. However, the
multiple variables typically inherent in the transition from two-
dimensional to three-dimensional make it difficult to define the
underlying mechanisms and importance of these changes. Therefore,
to investigate the multicellular interactions involved in tumor growth
and angiogenesis, we hypothesized that a multicellular scaffold-free
aggregate formed as a consequence of gravity-enforced self-assembly
in a self-contained microenvironment may be instructive. The use of
gravity-enforced cell assembly has multiple potential benefits. It
allows for precise size control preventing oxygen and nutrient limita-
tions and is compatible with a variety of cell types; moreover, cell
mobility during assembly enables natural intercellular organization.
It also facilitates the development of an extracellular matrix, without
interfering with cell regulatory networks. In addition, because it re-
quires very low volumes, it is compatible with high-throughput assay
systems. Although the in vitro model cannot account for all aspects of
tumor grown in vivo, our studies clearly show that multicellular spher-
oids composed of both tumor and endothelial cells when grown as
hanging drops have altered properties for treatment response in vitro
and enhance tumor growth, angiogenesis, and progression when im-
planted in vivo. Nevertheless, the multicellular spheroid may allow
more accurate modeling of the initial primary or micrometastatic
stages of solid tumor progression than would be possible in a living
Figure 7. Increase in growth and aggressive metastasis to the lung of tumors originating from tumor-endothelial cell spheroids. (A)
Tumors derived from tumor-endothelial cell spheroids implanted in rear limb of athymic nude mice exhibited enhanced growth rate
in comparison to those derived from tumor cell–only spheroids. Values on the y axis represent the relative tumor volume (the ratio of
tumor volume at day 33 to the tumor volume on the day palpable tumors were observed in the mice with 4T1 tumor spheroid implants).
Results represent mean ± SD (n = 3). There is a significant difference (P < .07) in the relative tumor volume between the 4T1-2H11 and
4T1 measurements (three mice each) at α = 0.01. Metastasis as observed by occurrence of diseased lungs with metastatic lesions was
more aggressive in mice with primary tumors originating from tumor-endothelial cell spheroids. (B) Image of lung under fluorescence
microscope at 4×. (C) Excised lungs at day 33 after implantation. (D) H&E-stained sections of lungs.
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tissue. The molecular and cellular factors that drive these processes,
and which treatment strategy best defeats them, are the ongoing focus
of work in our group.
Cocultivation of tumor and endothelial cells causes reprogram-
ming of the signaling in and between the two cell types, which results
in a phenotypic switch that includes growth, migration, activation, and
morphogenic changes like the formation of a network resembling the
neovasculature. There have been several studies that have reported these
changes to be associated with the coordinated changes of gene ex-
pression profiles from the tumor-endothelial interaction [33–36]. Co-
culture studies have also suggested various degrees of altered response of
tumor cells to radiation, cytotoxic or antiangiogenic agents, and gene
therapy [35,37–41]. The ability of these tumor-endothelial spheroids
to enhance angiogenesis and metastasis in vivo further authenticates
the importance of studying the crosstalk mechanisms between these cell
types. Molecular and immunohistochemical studies are underway to
characterize the “angiogenic switch” in the tumor-endothelial spheroids
developed in vitro. We are also examining other murine and mamma-
lian tumor and endothelial cell types to further establish this valuable
preclinical model system. Our initial results indicate that this model
may provide an excellent opportunity to comprehensively evaluate
cancer therapeutics against an environment similar to occult cancer
or micrometastases to generate more predictive preclinical data.
For example, using GFP-expressing 4T1 mouse mammary epithelial
cells and murine 2H11 endothelial cells, we have shown that the pres-
ence of endothelial cells in the tumor microenvironment alters the re-
sponse of the 4T1 tumor cells to both chemotherapy and radiation.
Our studies reveal that the 4T1 tumor cells, normally resistant to Taxol
at 2 μM [11], become sensitive to the same drug concentration when in
coculture with the 2H11 endothelial cells (Figure 3). Conversely, the
presence of endothelial cells in three-dimensional coculture with the
tumor cells makes the tumor cells more resistant to 2 Gy of radiation
(Figure 4). A better understanding of the tumor microenvironment
may explain and predict why many therapies do not reach the expected
level of activity in the patient.
Tumor spheroid implants in window chambers on the dorsal
skinfold of rodents have been used routinely in translational studies
[18,42–44]. Although some aspects of this model are artificial to true
solid tumor growth, the window chamber model allows unmatched
ability for longitudinal imaging of tumor growth and neovasculariza-
tion in the living animal [45–47]. Using multiwavelength intravital
imaging, we found rapid neovascularization in tumors originating
from tumor-endothelial spheroid window chamber implants in com-
parison to tumors initiated from tumor spheroids only, again indicative
of the functional significance of the presence of endothelial cells in the
microenvironment (Figure 5). These distinct differences in tumor
growth and vascularization were reflected in an antibody array based
molecular analysis of tumor lysates showing up-regulation of pro-
angiogenic factors in window chamber tumors originating from tumor-
endothelial spheroids within a span of 14 days after implantation
(Figure 6). Furthermore, our results in the window chamber were sup-
ported by another study where the growth of tumors in the rear limb
of mice and metastasis to the lung originating from tumor-endothelial
spheroids was much faster than in those from tumor spheroids alone
(Figure 7, A-D). Thus, we conclude that the coculture of tumor and
endothelial cells in the spheroids allows the process of tumor growth
and angiogenesis to be enhanced/accelerated in vivo and that certain
protein expression patterns, such as those we have identified, play a role
in this enhanced growth. In 1941, Greene first showed the ability of
avascular tumors to grow in the anterior chamber of the rabbit eye.
These avascular tumors, however, continued to remain dormant and
failed to grow when transplanted in the same way in guinea pigs
[48,49]. The initial studies of tumor cell implants in hind limb of rats
did result in large intramuscular tumors but no metastasis to the lung
[50]. We noted the similarity between these studies done long ago
showing the latency of avascular tumors to grow and metastasize in vivo
and our in vitro/in vivo studies where inclusion of 2H11 endothelial
cells in the GFP-4T1 tumor spheroids accelerated the process of tumor
growth and metastasis.
In summary, the hanging drop tumor-endothelial cell strategy in
vitro and subsequent transplant to the window chamber or rear limb
in vivo is a newly created preclinical model system to better under-
stand mechanisms governing tumor initiation, growth, angiogenesis,
and progression. In addition, the response of these systems to exper-
imental or established therapeutics will allow important observations
about the cellular, molecular, and physiological aspects of tumor re-
sponse. In addition, the importance of yet undefined modes of inter-
cellular communication and support between tumor and endothelial
cells may be uncovered to lead to new targets for cancer control.
Efforts in our group are directed toward developing and improving
strategies for tumor-specific radiation therapy and/or drug delivery,
by identifying surrogate markers of tumor progression, before and
after treatment.
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Figure W1. Spheroids at day 6 after addition of 200 (A) and 2000 (B) 4T1 tumor or 2H11 endothelial cells to the existing 4T1 hanging
drop culture.
